Onconetix annual return on equity
2022
2023
2024
2025
Onconetix Return on Equity (ROE) Growth & History (ONCO)
Onconetix's return on equity was −115.46% for fiscal 2025.
View full Onconetix company overviewOnconetix annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −115.46% | +3876.32 pp |
| 2024 | 2024-12-31 | −3,991.77% | −3546.05 pp |
| 2023 | 2023-12-31 | −445.73% | −333.12 pp |
| 2022 | 2022-12-31 | −112.61% | — |
Onconetix quarterly return on equity
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −22.74% | +25.17 pp |
| Q1 2026 | 2026-03-31 | −30.64% | +105.71 pp |
| Q4 2025 | 2025-12-31 | 59.25% | +197.93 pp |
| Q3 2025 | 2025-09-30 | −189.22% | — |
| Q2 2025 | 2025-06-30 | −47.92% | — |
| Q1 2025 | 2025-03-31 | −136.35% | — |
| Q4 2024 | 2024-12-31 | −138.68% | +825.88 pp |
| Q4 2023 | 2023-12-31 | −964.56% | −951.19 pp |
| Q3 2023 | 2023-09-30 | −45.87% | −29.17 pp |
| Q2 2023 | 2023-06-30 | −41.90% | −18.92 pp |
| Q1 2023 | 2023-03-31 | −13.53% | +9.50 pp |
| Q4 2022 | 2022-12-31 | −13.38% | — |
| Q3 2022 | 2022-09-30 | −16.70% | — |
| Q2 2022 | 2022-06-30 | −22.98% | — |
| Q1 2022 | 2022-03-31 | −23.03% | — |
Onconetix return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Onconetix's return on equity decreased from −112.61% to −115.46%, a change of −2.85 percentage points. The latest reported quarter, Q2 2026, shows −22.74%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Onconetix source filings ↗